Hopp til innhold
NHI.no
Annonse

Hjerteamyloidose: Symptomer

Innhold i artikkelen

Tidlig i forløpet er det lite symptomer som skriver seg fra hjertet. Når sykdomsbildet er utviklet, er de mest typiske symptomene hovne ben, struttende vener på halsen, forstørret lever og tungpusthet. Noen har lett for å besvime som følge av langsom puls og lavt blodtrykk. Slapphet og vekttap er vanlig.

Annonse

Andre organer enn hjertet kan være angrepet, blant annet kan det være tegn på nyre- og leverskade, perifere nerveskader, som karpal tunnel syndrom i hendene og spinal stenose.

Dette dokumentet er basert på det profesjonelle dokumentet Hjerteamyloidose . Referanselisten for dette dokumentet vises nedenfor

  1. Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018;18(Suppl 2):s30-s35. www.ncbi.nlm.nih.gov
  2. Fontana M. Cardiac amyloidosis: Clinical manifestations and diagnosis. UpToDate, last updated Nov 14, 2019. UpToDate
  3. Wien TN, Kvam AK, Stensland M, et al. Veileder for diagnostikk og behandling av amyloidose. Sist oppdatert 21.12.2021. Siden lest 30.08.2023. www.helsebiblioteket.no
  4. Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28(1):10-21. doi:10.1016/j.tcm.2017.07.004 DOI
  5. González-López E, López-Sainz Á, Garcia-Pavia P. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope. Rev Esp Cardiol (Engl Ed). 2017;70(11):991-1004. PubMed
  6. AbouEzzeddine OF, Davies DR, Scott CG, et al. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 2021. pmid:34431962 PubMed
  7. Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232-239. doi:10.1080/07853890701842988 DOI
  8. Fontana M, Banypersad SM, Treibel TA, et al. Differential Myocyte Responses in Patients with Cardiac Transthyretin Amyloidosis and Light-Chain Amyloidosis: A Cardiac MR Imaging Study. Radiology. 2015;277(2):388-397. doi:10.1148/radiol.2015141744 DOI
  9. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-2060. doi:10.1161/CIRCULATIONAHA.104.489187 DOI
  10. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J. 2012;33(9):1120-1127. doi:10.1093/eurheartj/ehr383 DOI
  11. Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26(11):2317-2325. doi:10.1038/leu.2012.100 DOI
  12. Longhi S, Quarta CC, Milandri A, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid 2015; 22:147. PubMed
  13. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016;133(24):2404-2412. doi:10.1161/CIRCULATIONAHA.116.021612 DOI
  14. Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119(19):4387-4390. doi:10.1182/blood-2011-10-388462 DOI
  15. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 2018; 379:1007. New England Journal of Medicine
  16. Muchtar E, Jevremovic D, Dispenzieri A, et al. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. Blood. 2017;129(1):82-87. doi:10.1182/blood-2016-06-721878 DOI
Annonse
Annonse